< Back to situations

[ORGANIZATION]

American Society of Clinical Oncology

Featured in 6 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

216 clusters · 804 sources · last updated

Latest: GLP-1 drugs face scrutiny over healthcare costs and bone health

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. While research suggests secondary benefits—including a 21% lower risk of fragili

[ACTIVE] [BUSINESS] [US]

Corcept Therapeutics stock volatility and insider trading

2 clusters · 4 sources · last updated

Latest: Corporate insiders execute various stock transactions

Corcept Therapeutics experienced a significant stock surge of approximately 228%, reaching a price of $117.17 by August 18, 2026. This growth was linked to an investment by Donald Trump, FDA support for a New Drug Applic

[QUIET] [HEALTH] [US] [AR] [CA]

Daraxonrasib trial shows doubled survival, EMA review on-go

31 clusters · 137 sources · last updated

Latest: Daraxonrasib doubles survival rates in pancreatic cancer trials

The rolling EMA review of the oral KRAS-targeting inhibitor daraxonrasib, launched on 7 July 2026, continues as new clinical data emerge. A multinational phase-III trial reported on 25 July that daraxonrasib doubled medi

[QUIET] [HEALTH] [AR] [BR] [MX]

Pfizer lorlatinib long‑term lung cancer results

2 clusters · 4 sources · last updated

Latest: Pfizer's lorlatinib cuts intracranial progression risk 94% in ALK‑positive lung cancer

Pfizer presented a seven‑year update of the phase III CROWN trial at the 2026 American Society of Clinical Oncology (ASCO) meeting. The trial compared lorlatinib with crizotinib as first‑line therapy for patients with ad

Also covered in